The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling

The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5

(2016) Huan-Tian Zhang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Dual Role of p21 in the Progression of Cancer and Its Treatment

(2016) Amna Parveen et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Molecular oncogenesis of chondrosarcoma

(2016) Frank M. Speetjens et al.   CURRENT OPINION IN ONCOLOGY

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma

(2016) H. K. Bid et al.   MOLECULAR CANCER THERAPEUTICS

Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation

(2015) Birgit Lohberger et al.   BMC CANCER

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1

(2015) Krishan Kumar et al.   Scientific Reports

A Novel PTEN/Mutant p53/c-Myc/Bcl-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy

(2015) Xiaoping Huang et al.   NEOPLASIA

Epigenetic drugs against cancer: an evolving landscape

(2014) Antonella Di Costanzo et al.   ARCHIVES OF TOXICOLOGY

Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells

(2014) Huan-Tian Zhang et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

BET Protein Inhibitor JQ1 Attenuates Myc-Amplified MCC Tumor Growth In Vivo

(2014) Q. Shao et al.   CANCER RESEARCH

Hippo-YAP signaling pathway: A new paradigm for cancer therapy

(2014) Yanlei Ma et al.   INTERNATIONAL JOURNAL OF CANCER

Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma

(2014) Dhong Hyun Lee et al.   INTERNATIONAL JOURNAL OF CANCER

BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction

(2014) S. Meng et al.   JOURNAL OF DENTAL RESEARCH

Targeting bromodomains: epigenetic readers of lysine acetylation

(2014) Panagis Filippakopoulos et al.   NATURE REVIEWS DRUG DISCOVERY

BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones

(2014) Tomohiko Kanno et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis

(2014) A R D Delbridge et al.   ONCOGENE

Alveolar rhabdomyosarcoma–associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression

(2013) Lisa E.S. Crose et al.   JOURNAL OF CLINICAL INVESTIGATION

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1

(2013) Helen Jayne Susan Stewart et al.   Cancer Medicine

Gatifloxacin Induces S and G2-Phase Cell Cycle Arrest in Pancreatic Cancer Cells via p21/p27/p53

(2012) Vikas Yadav et al.   PLoS One

Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice

(2011) P. N. Kelly et al.   BLOOD

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Plasmin-clipped β2-glycoprotein-I inhibits endothelial cell growth by down-regulating cyclin A, B and D1 and up-regulating p21 and p27

(2010) Wolf-Dietrich C. Beecken et al.   CANCER LETTERS

YAP is a candidate oncogene for esophageal squamous cell carcinoma

(2010) Tomoki Muramatsu et al.   CARCINOGENESIS

Prognostic significance of downregulated expression of programmed cell death 5 in chondrosarcoma

(2010) Changbao Chen et al.   JOURNAL OF SURGICAL ONCOLOGY

Chordoma and chondrosarcoma gene profile: implications for immunotherapy

(2008) Joseph H. Schwab et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY